All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

MOD GRF 1-29

MOD GRF 1-29 is a synthetic peptide designed to stimulate the natural release of growth hormone (GH) from the pituitary gland. It is a modified version of a shortened fragment of growth hormone-releasing hormone (GHRH), engineered to improve stability and biological activity. MOD GRF 1-29 is derived from the first 29 amino acids of Growth hormone–releasing hormone, which is the biologically active portion responsible for stimulating growth hormone secretion.

Because of its structural modifications, MOD GRF 1-29 is often referred to as “modified GRF (1-29)” and is studied in endocrine research related to growth hormone regulation.

How MOD GRF 1-29 works

MOD GRF 1-29 peptide acts by stimulating GHRH receptors in the pituitary gland, which triggers the natural pulsatile release of growth hormone. Research suggests that the peptide may:

  • stimulate physiological release of growth hormone

  • increase circulating levels of insulin-like growth factor-1 (IGF-1) through activation of the GH axis

  • support the normal pulsatile pattern of GH secretion produced by the body

Compared with the unmodified fragment GRF 1-29, the modified version includes several amino acid substitutions designed to:

  • increase resistance to enzymatic degradation

  • extend its biological activity in the body

  • improve its stability during experimental use

Because of these properties, MOD GRF 1-29 has been studied in research related to endocrine physiology, metabolism, and growth hormone regulation.

Clinical trials and evidence

Research involving MOD GRF 1-29 ghrh has primarily focused on hormone regulation and endocrine signaling. Experimental studies have examined:

  • stimulation of growth hormone release

  • interactions between GHRH analogues and growth hormone secretagogues

  • regulation of IGF-1 levels through the GH axis

Some research has also investigated the combined use of GHRH analogues with peptides that activate the ghrelin receptor, which may produce a synergistic effect on growth hormone secretion.

However, despite its biological activity, MOD GRF 1-29 has not progressed to widespread pharmaceutical approval, and most available information comes from laboratory research and early experimental studies.

Possible side effects of MOD GRF 1-29:

Because MOD GRF 1-29 influences the growth hormone axis, potential side effects may be related to changes in GH and IGF-1 signaling. Reported or possible effects may include:

  • headache

  • flushing

  • mild water retention

  • injection site reactions

  • temporary changes in appetite or fatigue

As with many investigational peptides affecting endocrine pathways, the long-term safety profile has not been fully established.

MOD GRF 1-29 is considered an experimental peptide studied primarily in endocrine and metabolic research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

MOD GRF 1-29
Action: Growth hormone release stimulation | Category: GHRH analog
Experimental dosage: 100 mcg | Frequency: 1–2× a day | Timing: evening | Cycle on: 8 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:AOD9604, CJC-1295 NO DAC, CJC-1295 with DAC, GHRP-2, GHRP-6, Hexarelin

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged